Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche sees Avastin approved for advanced kidney cancer

Roche sees Avastin approved for advanced kidney cancer

19th December 2007

Roche has announced that its anti-cancer drug Avastin has been approved in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC).

EU approval allows Avastin to be used in combination with interferon (IFN) which is the current standard of care for kidney cancer.

Roche received approval for Avastin’s indication in advanced RCC after the consideration of data drawn from the company’s phase III Avoren trial.

The clinical trial showed that patients with advanced RCC who received Avastin in combination with IFN lived nearly double the time without their disease progressing compared to those receiving only IFN treatment.

Professor Bernard Escudier, head of the Immunotherapy and Innovative Therapy Unit in Paris, commented that the Avoren study results confirmed that Avastin was a “safe, effective and well tolerated” treatment for patients with advanced RCC.

“Avastin effectively doubles the time in which patients live without their disease getting worse, so this approval has the potential to change the treatment landscape for this disease, where treatment options are still limited,” he highlighted.

Kidney cancer is the fourth cancer type for which Avastin has been indicated for with colorectal, breast and lung cancer indications all receiving approval.

Earlier this month, Roche announced the launch of a secondment scheme which will provide its employees with the opportunity to work in a developing country.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.